China’s Sansure Biotech Launches Approved Kit for Alzheimer’s and Cardiovascular Risk Assessment

Sansure Biotech Inc. (SHA: 688289), a China-based leader in molecular diagnostics, has secured marketing approval from the National Medical Products Administration (NMPA) for its human ApoE gene polymorphism nucleic acid detection kit, utilizing the PCR fluorescent probe method. This kit is classified as a Category III medical device.

The detection kit is designed for the qualitative analysis of T388C and C526T polymorphisms of the ApoE gene in DNA extracted from human peripheral blood samples. It aims to aid in the clinical monitoring of statin efficacy and offers valuable insights for assessing the risk of diseases such as Alzheimer’s, atherosclerosis, coronary heart disease, and cerebral infarction. Furthermore, it supports personalized diagnosis and treatment strategies.- Flcube.com

Fineline Info & Tech